0X40 Stock Overview
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
AgeX Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.44 |
| 52 Week High | US$23.56 |
| 52 Week Low | US$10.06 |
| Beta | 1.19 |
| 1 Month Change | 55.97% |
| 3 Month Change | 49.40% |
| 1 Year Change | -19.35% |
| 3 Year Change | -62.14% |
| 5 Year Change | n/a |
| Change since IPO | -88.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0X40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -19.3% | -19.9% | 0.9% |
Return vs Industry: 0X40 underperformed the German Biotechs industry which returned 35.8% over the past year.
Return vs Market: 0X40 underperformed the German Market which returned 6.4% over the past year.
Price Volatility
| 0X40 volatility | |
|---|---|
| 0X40 Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0X40's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0X40's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Joanne Hackett | www.agexinc.com |
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology.
AgeX Therapeutics, Inc. Fundamentals Summary
| 0X40 fundamental statistics | |
|---|---|
| Market cap | €29.02m |
| Earnings (TTM) | -€13.63m |
| Revenue (TTM) | €130.77k |
221.9x
P/S Ratio-2.1x
P/E RatioIs 0X40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0X40 income statement (TTM) | |
|---|---|
| Revenue | US$142.00k |
| Cost of Revenue | US$40.00k |
| Gross Profit | US$102.00k |
| Other Expenses | US$14.91m |
| Earnings | -US$14.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.92 |
| Gross Margin | 71.83% |
| Net Profit Margin | -10,424.65% |
| Debt/Equity Ratio | 81.5% |
How did 0X40 perform over the long term?
See historical performance and comparison